| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
APG-2449 is an orally administered kinase inhibitor that inhibits receptor tyrosine kinases anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK), and receptor tyrosine kinase C-ros oncogene 1 (ROS1), exhibiting potential antitumor activity. Upon administration, the ALK/FAK/ROS1 inhibitor APG-2449 selectively binds to and inhibits ALK, FAK, and ROS1 kinases. This inhibition disrupts ALK, FAK, and ROS1-mediated signal transduction pathways, ultimately inhibiting the growth of ALK, FAK, and ROS1-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays a crucial role in nervous system development; its dysfunction and gene rearrangements are associated with various tumors. Cytoplasmic tyrosine kinase FAK is an integrin signaling molecule that is upregulated and persistently activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ROS1 is overexpressed in some cancer cells and plays a crucial role in cancer cell growth and survival.
|
| Molecular Formula |
C33H42CLN5O4S
|
|---|---|
| Molecular Weight |
640.235685825348
|
| Exact Mass |
639.264
|
| CAS # |
2196186-84-0
|
| PubChem CID |
138678712
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
6.9
|
| tPSA |
114
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
44
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=C(C=C1C2=CCN(CC2)C3CCOCC3)OC(C)C)NC4=NC=C(C(=N4)NC5=CC=CC=C5S(=O)(=O)C(C)C)Cl
|
| InChi Key |
YWPHBSHEGTZPNS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H42ClN5O4S/c1-21(2)43-30-19-26(24-10-14-39(15-11-24)25-12-16-42-17-13-25)23(5)18-29(30)37-33-35-20-27(34)32(38-33)36-28-8-6-7-9-31(28)44(40,41)22(3)4/h6-10,18-22,25H,11-17H2,1-5H3,(H2,35,36,37,38)
|
| Chemical Name |
5-chloro-2-N-[5-methyl-4-[1-(oxan-4-yl)-3,6-dihydro-2H-pyridin-4-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~25 mg/mL (~39.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5619 mL | 7.8096 mL | 15.6191 mL | |
| 5 mM | 0.3124 mL | 1.5619 mL | 3.1238 mL | |
| 10 mM | 0.1562 mL | 0.7810 mL | 1.5619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03917043
Conditions:Advanced Solid Cancer|Non Small Cell Lung Cancer|Esophageal Cancer|Ovarian Cancer|Malignant Pleural MesotheliomaLink: https://clinicaltrials.gov/ct2/show/NCT06687070
Conditions:Platinum-resistant Recurrent Ovarian Cancer|Advanced Solid Tumor